Funding for this research was provided by:
Wellcome Trust (110043/Z/15/Z, 107116/Z/15/Z)
Medical Research Council (MR/S006990/1)
Horizon 2020 Framework Programme (739572)
Received: 29 February 2020
Accepted: 1 March 2020
First Online: 17 March 2020
Ethics approval and consent to participate
: SMALED2 patient and control fibroblasts were obtained with consent from the MRC CNMD Biobank, London which has been approved by the West London & GTAC Research Ethics Committee (06/Q0406/33) and is licensed by the Human Tissue Authority (license number: 12198). Animal experimentation was performed under license from the United Kingdom Home Office in accordance with the Animals (Scientific Procedures) Act (1986), and approved by the University College London Queen Square Institute of Neurology ethics committee.
: Not applicable.
: The authors declare that they have no competing interests.